- Anti-inflammatory
- Anti-infective
- Anti-glaucoma
- Anti-allergy
- Anti-VEGF agents
Ophthalmic Drugs Market size was valued at USD 61.8 billion in 2023 and is poised to grow at a 8.3% CAGR from 2024 to 2030. Ophthalmic drugs are medications used to treat various eye conditions and diseases. The increasing prevalence of eye disorders such as glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy is expected to drive the growth of the ophthalmic drugs market over the forecast period. In addition, the aging global population and rising awareness about eye health are anticipated to boost market growth significantly. Technological advancements in drug delivery systems, such as sustained-release formulations, ocular implants, and microspheres, are revolutionizing ophthalmic treatments by improving patient compliance and treatment efficacy. For instance, in October 2021, Roche (Genentech) received FDA approval for Susvimo (ranibizumab injection), a refillable ocular implant for the treatment of wet age-related macular degeneration (AMD). Susvimo is designed to continuously deliver a customized formulation of ranibizumab over a period of months, reducing the frequency of eye injections from as often as monthly to twice per year. However, the market faces certain restraints, including the high cost of innovative ophthalmic drugs, which limits accessibility, and stringent regulatory requirements that prolong the time-to-market for new products.
Side effects associated with long-term use of certain ophthalmic medications and patent expirations of blockbuster drugs leading to generic competition also pose challenges to market growth. Despite these obstacles, the market presents numerous opportunities, particularly in emerging markets with large untapped patient populations. The development of personalized medicine in ophthalmology, increasing adoption of telemedicine and digital health solutions in eye care, and growing potential for gene therapies and stem cell treatments offer promising avenues for market expansion. Rising demand for combination therapies to enhance treatment efficacy also contributes to market opportunities. Current trends in the ophthalmic drugs market include a shift towards minimally invasive drug delivery systems, increasing focus on the development of biologics for eye disorders, and growing popularity of preservative-free formulations. The rise of artificial intelligence in drug discovery and personalized treatment plans, along with increasing collaborations between pharmaceutical companies and research institutions, are shaping the future of ophthalmic drug development.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The ophthalmic drug market is primarily driven by two significant factors, the increasing prevalence of eye disorders and technological advancements in drug delivery systems. The rising incidence of eye diseases, particularly among the aging global population, is a major catalyst for market growth. Conditions such as glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are becoming more common, creating a sustained demand for effective ophthalmic treatments. This demographic trend is complemented by growing awareness about eye health, leading to earlier diagnosis and treatment of eye conditions. Simultaneously, technological innovations in drug delivery systems are revolutionizing ophthalmic therapies. The development of sustained-release formulations, such as ocular implants and microspheres, is addressing the challenge of patient compliance in long-term eye treatments. These advanced delivery methods ensure a consistent therapeutic effect over extended periods, reducing the frequency of drug administration and improving overall treatment outcomes. Such innovations are not only enhancing patient experience but also opening new avenues for treating complex eye disorders.
The Ophthalmic Drugs Market was valued at USD 61.8 billion in 2023 and is expected to grow at a 8.3% CAGR from 2024 to 2030.
The Ophthalmic Drugs market is segmented based on type, application, end user, and geography.
The leading players in the global Ophthalmic Drugs market include Novartis AG, Regeneron Pharmaceuticals, Allergan (AbbVie), Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Roche Holding AG, Johnson & Johnson Vision, and Sun Pharmaceutical Industries Ltd.
Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation, and a seven-year forecast is presented from 2024 to 2030.
1.Executive Summary |
2.Global Ophthalmic Drugs Market Introduction |
2.1.Global Ophthalmic Drugs Market - Taxonomy |
2.2.Global Ophthalmic Drugs Market - Definitions |
2.2.1.Type |
2.2.2.Application |
2.2.3.End User |
2.2.4.Region |
3.Global Ophthalmic Drugs Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Ophthalmic Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Ophthalmic Drugs Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Anti-inflammatory |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Anti-infective |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Anti-glaucoma |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Anti-allergy |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Anti-VEGF agents |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Ophthalmic Drugs Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Retinal Disorders |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Glaucoma |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Dry Eye |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Allergies |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Infections |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Ophthalmic Drugs Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Ophthalmic Clinics |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Retail Pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Ophthalmic Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Anti-inflammatory |
9.1.2.Anti-infective |
9.1.3.Anti-glaucoma |
9.1.4.Anti-allergy |
9.1.5.Anti-VEGF agents |
9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Retinal Disorders |
9.2.2.Glaucoma |
9.2.3.Dry Eye |
9.2.4.Allergies |
9.2.5.Infections |
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Ophthalmic Clinics |
9.3.3.Retail Pharmacies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Anti-inflammatory |
10.1.2.Anti-infective |
10.1.3.Anti-glaucoma |
10.1.4.Anti-allergy |
10.1.5.Anti-VEGF agents |
10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Retinal Disorders |
10.2.2.Glaucoma |
10.2.3.Dry Eye |
10.2.4.Allergies |
10.2.5.Infections |
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Ophthalmic Clinics |
10.3.3.Retail Pharmacies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Anti-inflammatory |
11.1.2.Anti-infective |
11.1.3.Anti-glaucoma |
11.1.4.Anti-allergy |
11.1.5.Anti-VEGF agents |
11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Retinal Disorders |
11.2.2.Glaucoma |
11.2.3.Dry Eye |
11.2.4.Allergies |
11.2.5.Infections |
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Ophthalmic Clinics |
11.3.3.Retail Pharmacies |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Anti-inflammatory |
12.1.2.Anti-infective |
12.1.3.Anti-glaucoma |
12.1.4.Anti-allergy |
12.1.5.Anti-VEGF agents |
12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Retinal Disorders |
12.2.2.Glaucoma |
12.2.3.Dry Eye |
12.2.4.Allergies |
12.2.5.Infections |
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Ophthalmic Clinics |
12.3.3.Retail Pharmacies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Anti-inflammatory |
13.1.2.Anti-infective |
13.1.3.Anti-glaucoma |
13.1.4.Anti-allergy |
13.1.5.Anti-VEGF agents |
13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Retinal Disorders |
13.2.2.Glaucoma |
13.2.3.Dry Eye |
13.2.4.Allergies |
13.2.5.Infections |
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Ophthalmic Clinics |
13.3.3.Retail Pharmacies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG |
14.2.2.Regeneron Pharmaceuticals |
14.2.3.Allergan (AbbVie) |
14.2.4.Bausch + Lomb |
14.2.5.Santen Pharmaceutical Co., Ltd. |
14.2.6.Bayer AG |
14.2.7.Pfizer Inc. |
14.2.8.Roche Holding AG |
14.2.9.Johnson & Johnson Vision |
14.2.10.Sun Pharmaceutical Industries Ltd. |
15. Research Methodology |
16. Appendix and Abbreviations |